by Marc Yates
If left untreated, hepatitis C leads to chronic health problems putting a huge strain on national healthcare resources.
by Jeff Elton
By offering pre-treatment services, pharma can become the "go to" resource from the start of the patient journey.
Why this trend has surfaced and key considerations for pharmaceutical companies actively exploring their own collaborations.
by Jeff Elton
Value-based reimbursement and contracting will become mainstream as reimbursement authorities move away from ‘cost’ as the focus towards ‘value.’
Most physicians are likely to overestimate their own patients’ adherence rates, according to a Healthprize survey.
It took a while, but the pharma industry is finally becoming aware that digital approaches may hold the key to transforming the way they market drugs and interact with their customers.
Healthcare spending in China has more than doubled from $156bn in 2006 to $357bn in 2011 and is estimated to reach $1tn by 2020 – about 6 per cent of the country’s GDP.
In order to remain competitive, pharmaceutical companies must shift their focus to smaller, more targeted patient populations.
FORUM Pharmaceuticals CEO and President Deborah Dunsire made the move from the oncology sphere into dementia-related illnesses. She tells Danielle Barron why she likes to stay at the cutting edge of research, while always keeping her eye on the prize – better outcomes for patients.